All Vaccinology articles
-
NewsVaccinated patients hospitalized with COVID-linked acute kidney injury less likely to need dialysis after discharge
Vaccinated patients hospitalized with COVID-19 who developed acute kidney injury had better outcomes than unvaccinated patients with the same condition, new research suggests. The study found vaccinated patients were less likely to stay on dialysis after discharge, and more likely to survive, than unvaccinated patients.
-
NewsAn oral cholera vaccination campaign aims to reach more than 2.6 million people in Sudan’s Khartoum State
A 10-day reactive oral cholera vaccination campaign, launched on 10 June in 5 localities in Sudan’s Khartoum State, aims to protect more than 2.6 million people aged 1 year and above from cholera infection, interrupt transmission and help contain the cholera outbreak.
-
NewsPeople with inflammatory RMD tolerate zoster vaccine well, study finds
New work presented at the 2025 annual EULAR congress in Barcelona focuses on the recombinant zoster vaccine (RZV), which contains recombinant glycoprotein E – the major target of CD4+T-cells. The abstract describes the tolerability and safety of RZV in patients with inflammatory rheumatic and musculoskeletal diseases (iRMD).
-
NewsSHEA affirms trust in ACIP and supports science-based vaccine policy
Public health experts have commented on the removal by the US Department of Health and Human Services (HHS) of all 17 members of the Advisory Committee on Immunization Practices (ACIP), which advises the Centers for Disease Control and Prevention (CDC) on the use of vaccines in the US.
-
NewsResearchers pioneer nanoparticle approach to fight poultry disease
Researchers have demonstrated that a novel protein-based nanoparticle can make mRNA vaccines more effective to tackle a troublesome pathogen in chickens.
-
NewsGlobal Virus Network issues scientific guidance on new COVID-19 variant NB.1.8.1 and vaccine protection
The Global Virus Network (GVN) is closely monitoring the emergence of a newly identified SARS-CoV-2 variant, NB.1.8.1, a sublineage of the Omicron family first identified in January 2025 and which has rapidly spread across Asia and into other regions.
-
NewsGlobal study: COVID-19 and adenoviral vaccines tied to GBS risk, not mRNA vaccines
A large-scale study in a population covering more than 230 million people sheds light on the relationship between Guillain-Barré syndrome after COVID-19 vaccines or SARS-CoV-2 infection.
-
NewsNew mRNA vaccine is more effective and less costly to develop, Pitt study finds
A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a study.
-
NewsNew data shows MMR vaccination rate decline across US
A new county-level dataset reveals a national decline in the measles-mumps-rubella (MMR) vaccination rate among U.S. children since the start of the COVID-19 pandemic.
-
NewsEarlier measles vaccine could help curb global outbreak
The global measles outbreak must trigger an urgent debate into whether a vaccine should be recommended earlier to better protect against the highly contagious disease during infancy, a new review states.
-
CareersHow structural imaging is revolutionising vaccines
Dr. Peijun Zhang, Director of the Electron Bio-Imaging Centre (eBIC) at the UK’s national synchrotron facility Diamond Light Source, reveals how Cryo-ET is powering some of the most important advances in vaccine research.
-
NewsEngineered bacteria can deliver antiviral therapies and vaccines
New research demonstrates how specially engineered bacteria taken orally can operate as a delivery system for antiviral therapies and vaccines.
-
NewsParticles carrying multiple vaccine doses could reduce the need for follow-up shots
Researchers are working to develop microparticles that can release their payload weeks or months after being injected. This could lead to vaccines that can be given just once, with several doses that would be released at different time points.
-
NewsTwo HIV vaccine trials show proof of concept for pathway to broadly neutralizing antibodies
A new study combining data from two separate phase 1 clinical trials shows that a targeted vaccine strategy can successfully activate early immune responses relevant to HIV, and, in one trial, further advance them.
-
NewsProof of concept for HIV vaccination that deploys germline-targeting
For a preventative HIV-vaccine to work it should induce broadly neutralising antibodies against all the diverse strains of the virus. The first in-human assessment of germline-targeting strategy with a trimer displays positive results.
-
NewsYellow fever vaccination: how strong immune responses are triggered
Researchers have shown how specific immune cells are activated by the vaccine – an important starting point for the development of new vaccines.
-
NewsNew study offers insights into designing safe, effective nasal vaccines
Researchers found that nasal vaccine boosters can trigger strong immune defenses in the respiratory tract, even without the help of immune-boosting ingredients known as adjuvants. The findings, researchers suggest, may offer critical insights into developing safer, more effective nasal vaccines in the future.
-
NewsNew vaccine protects against swine, human and bird flu
Annual flu shots could become a thing of the past under a new vaccine strategy. A new study describes a vaccine that protects against H1N1 swine flu and can also protect against influenza in humans and birds.
-
NewsResearchers pioneer novel, needle-free, live-attenuated influenza vaccines with broad protection
Researchers have achieved a significant breakthrough in developing broadly protective, live-attenuated influenza vaccines (LAIV).
-
NewsPredictive AI model can help build vaccines for future versions of a virus
Researchers have created an AI tool called EVE-Vax that can predict and design viral proteins likely to emerge in the future. For SARS-CoV-2, panels of these “designer” proteins triggered similar immune responses as real-life viral proteins that emerged during the pandemic.